Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.43 |
| ▸ | HTR2C | P28335 | 11/20 | 0.43 |
| ▸ | HTR2B | P41595 | 11/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11958056 | 0.86 | MDM2 (0.47) | HTR2AHTR2CHTR2BKCNH2HTR3E | |
| SCHEMBL11979897 | 0.86 | MDM2 (0.47) | HTR2AHTR2CHTR2BKCNH2HTR3E | |
| SCHEMBL11979628 | 0.86 | MDM2 (0.47) | HTR2AHTR2CHTR2BKCNH2HTR3E | |
| SCHEMBL26948157 | 0.82 | HTR2A (0.50) | HTR2AHTR2CHTR2BKCNH2ADRB1 | |
| SCHEMBL11958760 | 0.81 | MDM2 (0.43) | HTR2AHTR2CHTR2BKCNH2MDM2 | |
| SCHEMBL26938937 | 0.81 | L3MBTL1 (0.45) | HTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL30179232 | 0.80 | HTR2A (0.43) | HTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL21876550 | 0.80 | HTR2A (0.43) | HTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL20708219 | 0.80 | CHRM2 (0.42) | HTR2AHTR2CHTR2BKCNH2ADRB1 | |
| SCHEMBL29327276 | 0.80 | HTR2C (0.41) | HTR2AHTR2CHTR2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238281-A1 | PIPERAZINE DERIVATIVES AND APPLICATION THEREOF | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238281-A1 | PIPERAZINE DERIVATIVES AND APPLICATION THEREOF | AQP3, SLC6A7, ABCG2 | HTR2A 774/4885HTR2C 491/4885HTR2B 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.